 Home > Active Ingredient News > Drugs Articles > Express is expected to bring a full oral treatment plan for hepatitis B functional cure, complete the first administration of RNA destabilizer

Express is expected to bring a full oral treatment plan for hepatitis B functional cure, complete the first administration of RNA destabilizer

 Last Update: 2021-08-28
 Source: Internet
 Author: User

Tags

ibandronate side effects

newcastle disease virus

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On August 16, 2021, Enanta Pharmaceuticals announced that the phase 1 clinical trial of EDP-721 has completed the first administration

EDP-721 is a new oral RNA destabilizing agent (destabilizer), as part of the all-oral combination therapy being developed for the treatment of chronic hepatitis B virus (HBV) infection, hepatitis B aims to achieve functional cure

Hepatitis B is a viral infection that attacks the liver and can cause acute and chronic diseases

EDP-721 is a selective inhibitor of atypical polyadenylic acid polymerases PAPD5 and PAPD7.

EDP-721 is a selective inhibitor of atypical polyadenylic acid polymerases PAPD5 and PAPD7, these two proteins are key host factors for maintaining the stability of HBV RNA

▲EDP-721 reduced HBsAg levels by 3 log10 IU/mL in animal models (picture source: Enanta Pharmaceuticals official website)

This two-part phase 1a/b trial will initially evaluate the safety, tolerability, and pharmacokinetics of EDP-721 in healthy volunteers as a single dose and multiple incremental oral administrations

▲The combination of nucleoside analogues, EDP-514, and EDP-721 constitutes a full oral therapy that has the potential to functionally cure hepatitis B (picture source: Enanta Pharmaceuticals official website)

"We are very pleased to advance our HBV project.

Reference materials:

[1] Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721.

[1] Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721.
Its Oral Hepatitis B Virus RNA Destabilizer.
Retrieved August 16.
2021.
from https:// en/Enanta-Pharmaceuticals-Doses-First-Subject-in-a-Phase-1-Clinical-Study-of-EDP-721-Its-Oral-Hepatitis-B-Virus-RNA-Destabilizer

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Best price Pure Tirzepatide powder 10mg vial Tirzepatide CAS 2023788-19-2 ouda

CAS No.: 2023788-19-2

Pharmacy Grade

$40.00/G FOB

Safe Delivery Freeze Dried Peptides Raw Powder Weight Loss Tirze Peptide Sema 5mg 10mg

CAS No.: 2023788-19-2

Pharmacy Grade

$120.00/UNIT FOB

RU 58841 CAS 154992-24-2 RU58841 Powder Bulk RU-58841 For Hair Growth and Anti Hair Loss

CAS No.: 154992-24-2

Pharmacy Grade

$1-1.2/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.